Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dihydrocapsiate 可用于研究代谢疾病,是二氢 capsinoid 家族的一种化合物。Dihydrocapsiate 口服有效的 TRPV1激动剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 2,520 | 5日内发货 | ||
25 mg | ¥ 9,870 | 6-8周 | ||
50 mg | ¥ 13,100 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | Dihydrocapsiate is a compound of capsinoid family that can be used in metabolism diseas research. Dihydrocapsiate is an orally active agonist of TRPV1 [1]. |
体外活性 | Dihydrocapsiate (10, 25 and 50 μM; 48 hours; human preadipocytes) does not affect cell viability [1]. Dihydrocapsiate (10 and 20 μM; 8 days; mature adipocytes) markedly decreases the expression levels of other adipogenic markers (such as SREBP1, FABP4, PLIN1, ADIPOQ and LEPTIN) and inflammatory markers (MCP1 and TNFα), whereas it enhances the expression levels of PGC1α (master regulator of mitochondrial biogenesis) and TBX1 (marker of “brite” cell) [1]. Dihydrocapsiate (25~200 μM; RAW 264.7 cells) prevents NO release and intracellular ROS generation [1]. Cell Viability Assay [1] Cell Line: Human preadipocytes Concentration: 10, 25 and 50 μM Incubation Time: 48 hours Result: Did not affect cell viability. RT-PCR [1] Cell Line: Mature adipocytes Concentration: 10 and 20 μM Incubation Time: 8 days Result: Markedly decreased the expression levels of other adipogenic markers (such as SREBP1, FABP4, PLIN1, ADIPOQ and LEPTIN) and inflammatory markers (MCP1 and TNFα), whereas it enhanced the expression levels of PGC1α (master regulator of mitochondrial biogenesis) and TBX1 (marker of “brite” cell). |
体内活性 | Dihydrocapsiate (2 and 10 mg/kg; p.o.) improves morphometric parameters and insulin levels, prevents high fat diet (HFD)-induced adipocyte size and enhances energy expenditure-related genes in WAT, alleviates HFD-induced hepatic steatosis, prevents HFD-induced fat deposition and enhances mitochondrial biogenesis genes in BAT and improves intestinal morphology and modulates SCFA availability. Animal Model: HFD-fed mice [1] Dosage: 2 and 10 mg/kg Administration: P.o. Result: Improved morphometric parameters and insulin levels, prevented HFD-induced adipocyte size and enhanced energy expenditure-related genes in WAT, alleviated HFD-induced hepatic steatosis, prevented HFD-induced fat deposition and enhanced mitochondrial biogenesis genes in BAT and improved intestinal morphology and modulates SCFA availability. |
分子量 | 308.41 |
分子式 | C18H28O4 |
CAS No. | 205687-03-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dihydrocapsiate 205687-03-2 Inhibitor inhibitor inhibit